{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:37:53Z","timestamp":1761547073496,"version":"build-2065373602"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH-funded program","award":["P30 AR075042"],"award-info":[{"award-number":["P30 AR075042"]}]},{"name":"MGH Center for Skeletal Research"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>When denosumab is discontinued, antiresorptive therapy is necessary to mitigate high bone turnover bone loss. While bisphosphonates have been investigated for this, alternatives have received less attention. In the Comparison of Alendronate and Raloxifene after Denosumab (CARD) randomized, controlled, open-label study, we previously reported alendronate better suppressed bone remodeling and maintained denosumab-induced areal BMD (aBMD) gains than raloxifene, though raloxifene maintained femoral neck aBMD and partially inhibited loss elsewhere. In this exploratory analysis, we now assess the comparative ability of these drugs to maintain denosumab-induced improvements in peripheral volumetric BMD (vBMD), microarchitecture, and estimated bone strength. CARD randomized 51 postmenopausal women (60\u201381y) at high fracture risk to receive denosumab 60-mg by subcutaneous injection every 6 mo for 12-mo followed by either 12-mo of oral alendronate (70\u00a0mg weekly, n\u2009=\u200926) or oral raloxifene (60\u00a0mg daily, n\u2009=\u200925). Total, trabecular, and cortical vBMD and skeletal microarchitecture were measured by high-resolution peripheral quantitative CT of the distal radius and distal tibia. After 12-mo of denosumab, mean total and cortical vBMD at the radius and tibia increased significantly in the cohort as a whole, whereas trabecular vBMD did not change significantly. Bone strength (stiffness and failure load as estimated by finite element analysis) also increased significantly at both sites. After the transition to alternate antiresorptive therapy, the gains observed in total and compartmental vBMD and estimated bone strength were maintained in both treatment groups with no significant between-group differences. No significant changes in cortical porosity or thickness were observed, either during denosumab treatment or after the transition to alternate antiresorptive therapy. We conclude that denosumab improved vBMD and bone strength, and these gains were maintained with both alendronate and raloxifene, supporting raloxifene as an option for those unable or unwilling to take bisphosphonates after short-term denosumab exposure.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf156","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:22:44Z","timestamp":1758716564000},"source":"Crossref","is-referenced-by-count":0,"title":["The comparative efficacy of 12-mo of alendronate and raloxifene in maintaining denosumab-induced improvement in peripheral volumetric BMD, microarchitecture, and estimated strength"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy N","family":"Tsai","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabashini K","family":"Ramchand","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02114 ,","place":["United States"]},{"name":"Endocrine Unit, Cleveland Clinic, Lerner College of Medicine - Case Western Reserve University , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Jordan","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-236X","authenticated-orcid":false,"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA 02114 ,","place":["United States"]},{"name":"Biostatistics Center, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"8","key":"2025102702315475400_ref1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"volume":"33","journal-title":"J Bone Miner Res","issue":"2","key":"2025102702315475400_ref2"},{"issue":"2","key":"2025102702315475400_ref3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"key":"2025102702315475400_ref4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone."},{"issue":"2","key":"2025102702315475400_ref5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","article-title":"The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial","volume":"35","author":"Ramchand","year":"2024","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025102702315475400_ref6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jbmr.4161","article-title":"Effects of combination denosumab and high-dose teriparatide administration on bone microarchitecture and estimated strength: the DATA-HD HR-pQCT study","volume":"36","author":"Ramchand","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025102702315475400_ref7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/jbmr.297","article-title":"Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men","volume":"26","author":"Vilayphiou","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025102702315475400_ref8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S8756-3282(02)00736-6","article-title":"Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images","volume":"30","author":"Pistoia","year":"2002","journal-title":"Bone."},{"issue":"8","key":"2025102702315475400_ref9","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025102702315475400_ref10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study","volume":"30","author":"Tsai","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025102702315475400_ref11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jbmr.3707","article-title":"Effects of Denosumab and Teriparatide transitions on bone microarchitecture and estimated strength: the DATA-switch HR-pQCT study","volume":"34","author":"Tsai","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025102702315475400_ref12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025102702315475400_ref13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00223-022-00962-4","article-title":"Raloxifene use after Denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis","volume":"111","author":"Hong","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2025102702315475400_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4259","volume":"36","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025102702315475400_ref15","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1210\/clinem\/dgae240","article-title":"Bisphosphonates maintain BMD after sequential teriparatide and denosumab in premenopausal women with idiopathic osteoporosis","volume":"110","author":"Kamanda-Kosseh","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025102702315475400_ref16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025102702315475400_ref17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11657-018-0491-z","article-title":"Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study","volume":"13","author":"Silverman","year":"2018","journal-title":"Arch Osteoporos"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf156\/64380433\/ziaf156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/11\/ziaf156\/64380433\/ziaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/11\/ziaf156\/64380433\/ziaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:31:59Z","timestamp":1761546719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf156\/8263559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf156","relation":{},"ISSN":["2473-4039"],"issn-type":[{"type":"electronic","value":"2473-4039"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"ziaf156"}}